# RP-3467

Source: https://onco.cc/drugs/rp-3467/  
OnCo record `rp-3467` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RP-3467 is an experimental small molecule enzyme inhibitor from Repare Therapeutics, in phase 1 trials for epithelial ovarian cancer, metastatic breast cancer and metastatic castration-resistant prostate cancer and other cancers; its current status is not stated.

## Summary

RP-3467 is a small molecule enzyme inhibitor from Repare Therapeutics. A small-molecule inhibitor of the ATPase of DNA polymerase theta (Polθ), a synthetic-lethal target linked to BRCA mutations and other genomic changes; tested alone and with olaparib. Its furthest stage is phase 1, for epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer and pancreatic adenocarcinoma. ClinicalTrials.gov registers it in one study linked below. Phase 1 POLAR NCT06560632 terminated ('Sponsor decided to terminate study early'); Repare said in November 2025 it would no longer report POLAR topline data and was seeking to license the programme. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: RP-3467
- Modality: Small molecule enzyme inhibitor
- Mechanism: A small-molecule inhibitor of the ATPase of DNA polymerase theta (Polθ), a synthetic-lethal target linked to BRCA mutations and other genomic changes; tested alone and with olaparib.

## Sources

- Repare Therapeutics: sec.gov: https://www.sec.gov/Archives/edgar/data/1808158/000119312525159942/d944012dex991.htm
- Repare Therapeutics: sec.gov: https://www.sec.gov/Archives/edgar/data/1808158/000119312525283314/d39095dex991.htm
- Repare Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06560632
- ClinicalTrials.gov: trials of RP-3467: https://clinicaltrials.gov/search?intr=RP-3467

## Connected records

- targets: [POLQ](https://onco.cc/targets/polq/)
- companies: [Repare Therapeutics](https://onco.cc/companies/repare-therapeutics/)
- trials: [Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct06560632/)

---
JSON: https://onco.cc/api/v1/entities/rp-3467.json